Literature DB >> 19880446

The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis.

Andrea Mencarelli1, Barbara Renga, Marco Migliorati, Sabrina Cipriani, Eleonora Distrutti, Luca Santucci, Stefano Fiorucci.   

Abstract

Immune-mediated liver diseases including autoimmune and viral hepatitis are a major health problem worldwide. In this study, we report that activation of the farnesoid X receptor (FXR), a member of the ligand-activated nuclear receptor superfamily and bile sensor highly expressed in the liver, attenuates liver injury in a model of autoimmune hepatitis induced by Con A. We found that FXR gene ablation results in a time-dependent increase of liver expression (up to 20-fold in a 9-mo-old mouse) of osteopontin, a NKT cell-derived extracellular matrix protein and immunoregulatory cytokine. In comparison to wild-type, FXR(-/-) mice are more susceptible to Con A-induced hepatitis and react to Con A administration by an unregulated production of osteopontin. Administering wild-type mice with a synthetic FXR agonist attenuated Con A-induced liver damage and liver expression of the osteopontin gene. By in vitro studies, we found that FXR is expressed by primarily isolated NKT cells and its ablation favors ostepontin production in response to Con A. Chromatin immunoprecipitation assay and coimmunoprecipitation experiments demonstrate that the short heterodimer partner (SHP), a nuclear receptor and FXR target, was expressed by NKT cell hybridomas and increased in response to FXR activation. FXR activates SHP that interacts with and inhibits c-Jun binding to the osteopontin promoter. These data indicate that in NKT cells, FXR activation causes a SHP-mediated inhibition of osteopontin production. These data support the notion that the bile acid sensor FXR regulates the activation of liver NKT cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19880446     DOI: 10.4049/jimmunol.0901347

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  Deletion of IFNγ enhances hepatocarcinogenesis in FXR knockout mice.

Authors:  Zhipeng Meng; Xiaoqiong Wang; Yichao Gan; Yunfeng Zhang; Hong Zhou; Carl Van Ness; Jun Wu; Guiyu Lou; Hua Yu; Chao He; Rongzhen Xu; Wendong Huang
Journal:  J Hepatol       Date:  2012-06-21       Impact factor: 25.083

Review 2.  FXR Agonists: From Bench to Bedside, a Guide for Clinicians.

Authors:  Ahmad Samer Alawad; Cynthia Levy
Journal:  Dig Dis Sci       Date:  2016-10-12       Impact factor: 3.199

3.  Hepatocarcinogenesis in FXR-/- mice mimics human HCC progression that operates through HNF1α regulation of FXR expression.

Authors:  Nian Liu; Zhipeng Meng; Guiyu Lou; Weiping Zhou; Xiaoqiong Wang; Yunfeng Zhang; Lisheng Zhang; Xiyong Liu; Yun Yen; Lily Lai; Barry M Forman; Zhonggao Xu; Rongzhen Xu; Wendong Huang
Journal:  Mol Endocrinol       Date:  2012-04-02

Review 4.  Cross talk between neutrophils and the microbiota.

Authors:  Dachuan Zhang; Paul S Frenette
Journal:  Blood       Date:  2019-03-21       Impact factor: 22.113

Review 5.  Understanding the Holobiont: How Microbial Metabolites Affect Human Health and Shape the Immune System.

Authors:  Thomas Siegmund Postler; Sankar Ghosh
Journal:  Cell Metab       Date:  2017-06-15       Impact factor: 27.287

6.  Direct and Indirect Effects of Fibroblast Growth Factor (FGF) 15 and FGF19 on Liver Fibrosis Development.

Authors:  Justin D Schumacher; Bo Kong; Jason Wu; Daniel Rizzolo; Laura E Armstrong; Monica D Chow; Michael Goedken; Yi-Horng Lee; Grace L Guo
Journal:  Hepatology       Date:  2019-08-09       Impact factor: 17.425

Review 7.  Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis.

Authors:  Justin D Schumacher; Grace L Guo
Journal:  Handb Exp Pharmacol       Date:  2019

Review 8.  Dietary and metabolic modulators of hepatic immunity.

Authors:  Antonella Carambia; Johannes Herkel
Journal:  Semin Immunopathol       Date:  2017-11-06       Impact factor: 9.623

9.  FXR protects lung from lipopolysaccharide-induced acute injury.

Authors:  Lisheng Zhang; Tao Li; Donna Yu; Barry M Forman; Wendong Huang
Journal:  Mol Endocrinol       Date:  2011-12-01

Review 10.  Commensal bacteria at the interface of host metabolism and the immune system.

Authors:  Jonathan R Brestoff; David Artis
Journal:  Nat Immunol       Date:  2013-07       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.